Xcout Intel
OmniAb, Inc.
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
Subscribe to see OmniAb, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
OmniAb, Inc. at a glance
OmniAb, Inc. is a biotech company headquartered in EmeryVille, United States. It is publicly listed (OABI) with a market capitalisation of $629.5M. Xcout tracks 33 named people at OmniAb, Inc., including Matthew W Foehr (President, Chief Executive Officer & Director). Xcout recorded 1 job posting from OmniAb, Inc. in the last 90 days.
OmniAb, Inc. leadership
- Matthew W FoehrPresident, Chief Executive Officer & Director
- Amechi NwachukuExecutive VP & Chief Operating Officer
- Kurt A GustafsonExecutive Vice President of Finance & Chief Financial Officer
- Steve LoveChief Financial Officer
- Charles S. BerkmanChief Legal Officer
- John HigginsBoard Chair
27 more named people on record for OmniAb, Inc., with roles, board committees and tenure — see the full roster →
Hiring at OmniAb, Inc.
Xcout recorded 1 job posting from OmniAb, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see OmniAb, Inc.'s hiring signals →
Recent OmniAb, Inc. news
- PartnershipEli Lilly macht OmniAb-Deal: Kooperation für Ionenkanäle mit bis zu 370 Mio. USD Potenzial
2 corporate events on record, with sources — see the full timeline →
OmniAb, Inc. competitors
A few of OmniAb, Inc.'s closest competitors — see the full list of competitors and alternatives →
Prellis Biologics, Inc. is a privately held biotechnology company headquartered in Berkeley, California, within the San Francisco Bay Area. It develops human antibody therapeutics and focuses on antibody discovery leveraging AI and immune diversity.
AbbraTech Holdings LLC operates a platform technology focused on recombinant antibody discovery, engineering, and validation. The company targets human diseases such as cancer, immune disorders, and viral infections by developing antibodies for difficult-to-reach drug targets through its proprietary Epivolve technology.
Adimab is a biotechnology research company headquartered in Lebanon, New Hampshire, that serves as a biopharmaceutical industry partner for therapeutic antibody discovery and engineering.
Chiome Bioscience Inc. engages in the research and development of drug discovery technology platforms worldwide. It operates in two segments, Drug Discovery Business and Drug Discovery Support Business. The company offers ADLib System, a technology for generating monoclonal antibodies which is used to generate antibodies for drug discovery research; and Human ADLib System, which converts chicken antibody genes to humanized antibodies. It also provides protein expression and purification services; stable cell line development services for recombinant protein and antibody production; and antibody generation services using the ADLib system. In addition, the company's product pipeline under Phase 1 trial comprises ADCT-701, an anti-dlk1 antibody for treating liver cancer; CBA-1205, an afucosylated anti-dlk1 antibody for liver cancer, lung cancer, and neuroblastoma; and CBA-1535, an anti 5T4/WAIF1 antibody for malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, and triple negative breast cancer (TNBC). Further, its product pipeline under preclinical study includes PCDC, an anti- CDCP1 antibody for lung, colorectal, pancreatic, breast, and ovarian tumors; PTRY, an antibody 5T4/CD3/PD-L1 for treating malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, and TNBC; BMAA, an anti-semphorin3a antibody for treating renal and other diseases; LIV-2008/2008b, an anti-TROP-2 antibody for the treatment of TNBC, lung cancer, and colorectal cancer; PFKR, an anti-CX3CR1 antibody for secondary progressive multiple sclerosis; and PXLR, an anti-CXCL1/2/3/5 antibody for the treatment of gastric, breast, and ovarian tumors. Chiome Bioscience Inc. was incorporated in 2005 and is headquartered in Tokyo, Japan.
Chimagen Biosciences is a biopharmaceutical company headquartered in Shanghai, China, founded in July 2016. The company specializes in multi-specific antibody therapeutics and built the proprietary TRIAD platform for engineering.
BigHat Biosciences, Inc. is a for-profit biotechnology company located in California. The firm leverages machine learning and synthetic biology to design next-generation antibody therapies.
Get OmniAb, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on OmniAb, Inc. in Xcout Intel
- 33 named people with titles, LinkedIn and board committees
- Weekly hiring history and the mix of roles behind it
- 2 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access